Alliance Global Partners analyst Ben Haynor downgraded Viveve Medical to Neutral from Buy and dropped coverage of the name after the company announced the pivotal PURSUIT trial in stress urinary incontinence in women did not meet its primary endpoint nor several secondary endpoints. The analyst expects little interest from potential acquirers and sees little upside for shareholders.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VIVE:
- Viveve Nosedives on Delisting Plans after Clinical Trial Failure
- Viveve completes 12-month post-treatment follow-up visits in PURSUIT trial
- Viveve completes U.S. PURSUIT trial in female SUI
- Viveve announces issuance of U.S. method patent for treating female SUI
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue